Molbio Diagnostics (MOLBIO) — Financial Results

📢 Key Event
Q1 FY27 revenue of ₹408 crores with 25% EBITDA margin

🔄 What Changed
Revenue of ₹408 crores and PAT of ₹52.7 crores

🔮 What's Next
25% top line growth and 24-25% EBITDA margin guidance

💡 Investor Takeaway
Recurring revenue model from test kits now contributes 75% of revenue, signaling sustainable growth.

Molbio Diagnostics reported Q1 FY27 revenue of [amount context mismatch] crores with 25% EBITDA margin and [amount context mismatch] crores PAT, driven by Truenat platform growth and recurring kit sales. The company highlighted expansion into new markets, FDA approvals for OptraScan, and strategic acquisitions to scale diagnostics access globally.

📄 View Original Announcement (PDF)

📊 Stock Analysis — MOLBIO ✨ Ask AI About This

About Molbio Diagnostics Ltd (MOLBIO)

Healthcare · Healthcare · Listed on BSE

Market Cap: ₹16,255.48 Cr

View full MOLBIO stock details →

📡 Get AI alerts when MOLBIO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MOLBIO — Free

💡 Ask AI about this filing

"What is the revenue contribution split between devices and kits?" "When will HPV test commercial volumes begin?" "What is the timeline for US market entry with OptraScan?"

Ask AI Free →

📊 More MOLBIO filings

See all MOLBIO filings →

🔥 Also filed on 12 September 2026

KRYSTAL Krystal Integrated Services Ltd Announcement RPEL Raghav Productivity Enhancers Ltd Announcement SYMBIOTEC Symbiotec Pharmalab Ltd Insider Trading 516038 KS Smart Technlogies Limited Related Party Transaction WEWORK Wework India Management Ltd Board Meeting MASFIN MAS Financial Services Ltd Buyback / Redemption

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MOLBIO files new disclosures

Track MOLBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MOLBIO — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd